instruction
stringlengths 33
156
| input
float64 | output
stringlengths 120
1.97k
|
---|---|---|
Does Adalimumab and Polatuzumab vedotin interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Polatuzumab vedotin, and the severity of the interaction is minor. |
Does Adalimumab and Pomalidomide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Pomalidomide can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Ponatinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates with a narrow therapeutic index. In short, The metabolism of Ponatinib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Ponesimod interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Ponesimod can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Pozelimab interact? | null | Since pozelimab is an IgG4 antibody, co-administration of pozelimab with other immunoglobulins-based products can interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies, thus decreasing the serum concentration of pozelimab. In short, The serum concentration of Pozelimab can be decreased when it is combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Pralatrexate interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Pralatrexate, and the severity of the interaction is major. |
Does Adalimumab and Prasugrel interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Prasugrel can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Praziquantel interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Praziquantel can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Prednisolone interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Prednisolone, and the severity of the interaction is major. |
Does Adalimumab and Prednisone interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Prednisone, and the severity of the interaction is major. |
Does Adalimumab and Pretomanid interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Pretomanid can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Primaquine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Primaquine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Primidone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Primidone can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Procainamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Procainamide can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Procarbazine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Procarbazine, and the severity of the interaction is major. |
Does Adalimumab and Prochlorperazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Prochlorperazine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Progesterone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Progesterone can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Promazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Promazine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Promethazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Promethazine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Propafenone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Propafenone can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Propofol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Propofol can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Propranolol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Propranolol can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Propylthiouracil interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Propylthiouracil, and the severity of the interaction is major. |
Does Adalimumab and Quetiapine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Quetiapine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Quinidine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Quinidine can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Quinine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Quinine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Quizartinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Quizartinib can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rabeprazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Rabeprazole can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rabies immune globulin, human interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rabies virus inactivated antigen, A interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rabies virus inactivated antigen, B interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Raltitrexed interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Raltitrexed, and the severity of the interaction is major. |
Does Adalimumab and Ramelteon interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Ramelteon can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Ramucirumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Ramucirumab, and the severity of the interaction is minor. |
Does Adalimumab and Ranibizumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Ranibizumab, and the severity of the interaction is minor. |
Does Adalimumab and Ranitidine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Ranitidine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Ranolazine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Ranolazine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rasagiline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Rasagiline can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Ravulizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Ravulizumab, and the severity of the interaction is major. |
Does Adalimumab and Raxibacumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Raxibacumab, and the severity of the interaction is minor. |
Does Adalimumab and Regorafenib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Regorafenib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Relugolix interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Relugolix can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Repaglinide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Repaglinide can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Reslizumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Reslizumab, and the severity of the interaction is minor. |
Does Adalimumab and Resmetirom interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Resmetirom can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Respiratory syncytial virus vaccine, adjuvanted interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Revefenacin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Revefenacin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Ribociclib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Ribociclib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Rilonacept interact? | null | Although the combination of rilanocept with TNF inhibitors has not specifically been evaluated in clinical studies, the concomitant administration of anakinra, another IL-1 antagonist like rilonacept, with the anti-TNF agent etanercept resulted in greater incidences of adverse effects like serious infections, injection-site reactions, and neutropenia compared to etanercept monotherapy in clinical studies . As a consequence, there is a dangerous theoretical potential for the increased risk, incidence, and severity of adverse effects like infections and neutropenia to occur when rilanocept, an IL-1 antagonist, is used with an anti-TNF agent . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Rilonacept, and the severity of the interaction is major. |
Does Adalimumab and Rilpivirine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Rilpivirine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Riluzole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Riluzole can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Riociguat interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Riociguat can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Risankizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Risankizumab, and the severity of the interaction is major. |
Does Adalimumab and Risperidone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Risperidone can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Ritlecitinib interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Ritlecitinib, and the severity of the interaction is major. |
Does Adalimumab and Ritonavir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Ritonavir can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rituximab interact? | null | In rheumatoid arthritis pathophysiology, TNF-alpha plays a major role in joint inflammation, particularly by suppressing regulatory T cell activity.1,2 Therefore, adalimumab and other biologics that can target TNF-alpha have been used clinically to treat rheumatoid arthritis. However, due to their mechanism of action, concomitant use of adalimumab with other biologics can excessively inhibit TNF-alpha activity, thus dampening the body's immune response and increase risk of severe infection. In short, The risk or severity of infection can be increased when Adalimumab is combined with Rituximab, and the severity of the interaction is moderate. |
Does Adalimumab and Rivaroxaban interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Rivaroxaban can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Roflumilast interact? | null | Roflumilast is an inhibitor of phosphodiesterase-4 (PDE4). Inhibition of PDE4 affects the migration and actions of pro-inflammatory cells including neutrophils, other leukocytes, T-lymphocytes, monocytes, macrophages, and fibroblasts. According to multiple product monographs for roflumilast , there is insufficient data regarding the safety of concomitant use of roflumilast with immunosuppressive agents. Therefore, the use of roflumilast with long-term immunosuppressive therapy is not recommended. The use of short term systemic corticosteroids with roflumilast may be appropriate. In short, Roflumilast may increase the immunosuppressive activities of Adalimumab, and the severity of the interaction is minor. |
Does Adalimumab and Romidepsin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Romidepsin can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Romosozumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Romosozumab, and the severity of the interaction is minor. |
Does Adalimumab and Ropeginterferon alfa-2b interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Ropeginterferon alfa-2b, and the severity of the interaction is major. |
Does Adalimumab and Ropinirole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Ropinirole can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Ropivacaine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Ropivacaine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rosiglitazone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Rosiglitazone can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rosuvastatin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Rosuvastatin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rotavirus vaccine interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rotigotine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Rotigotine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Roxadustat interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Roxadustat can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rozanolixizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Rozanolixizumab, and the severity of the interaction is major. |
Does Adalimumab and Rubella virus vaccine interact? | null | In a placebo-controlled clinical trial of patients with RA, no difference was detected in antipneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Rubella virus vaccine, and the severity of the interaction is minor. |
Does Adalimumab and Rucaparib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Rucaparib can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Rupatadine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Rupatadine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Ruxolitinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates with a narrow therapeutic index. In short, The metabolism of Ruxolitinib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Sacituzumab govitecan interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Sacituzumab govitecan, and the severity of the interaction is minor. |
Does Adalimumab and Salicylic acid interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Salicylic acid can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Salmeterol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Salmeterol can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Saquinavir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Saquinavir can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Sarilumab interact? | null | In rheumatoid arthritis pathophysiology, TNF-alpha plays a major role in joint inflammation, particularly by suppressing regulatory T cell activity.1,2 Therefore, adalimumab and other biologics that can target TNF-alpha have been used clinically to treat rheumatoid arthritis. However, due to their mechanism of action, concomitant use of adalimumab with other biologics can excessively inhibit TNF-alpha activity, thus dampening the body's immune response and increase risk of severe infection. In short, The risk or severity of infection can be increased when Adalimumab is combined with Sarilumab, and the severity of the interaction is moderate. |
Does Adalimumab and Satralizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Satralizumab, and the severity of the interaction is major. |
Does Adalimumab and Saxagliptin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Saxagliptin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Secukinumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Secukinumab, and the severity of the interaction is major. |
Does Adalimumab and Selegiline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Selegiline can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Selexipag interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Selexipag can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Selumetinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Selumetinib can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Sertindole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Sertindole can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Sertraline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Sertraline can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Sevoflurane interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Sevoflurane can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Sildenafil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Sildenafil can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Siltuximab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Siltuximab, and the severity of the interaction is major. |
Does Adalimumab and Simvastatin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Simvastatin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Siponimod interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates with a narrow therapeutic index. In short, The metabolism of Siponimod can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Sipuleucel-T interact? | null | The concurrent use of chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given with the leukapheresis procedure of Sipuleucel-T has not been evaluated. Immunosuppressive agents may decrease the efficacy of Sipuleucel-T, which is an immunotherapeutic drug (enhancing immunity). This is due to the opposing effect of immunosuppressive and immunotherapeutic drugs. In short, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Sirolimus interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Sirolimus can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Sitagliptin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Sitagliptin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Smallpox (Vaccinia) Vaccine, Live interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Solifenacin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Solifenacin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Sonidegib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Sonidegib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Sorafenib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Sorafenib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Sotalol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Sotalol can be increased when combined with Adalimumab, and the severity of the interaction is major. |